Glucagon-Like Peptide-2 Therapy Outcomes Following Intestinal and Multivisceral Transplantation: A Multicenter Experience
Background: Glucagon-like peptide-2 (GLP-2) plays a vital role in intestinal adaptation, mucosal growth, and nutrient absorption. While GLP-2 therapy benefits patients with short bowel syndrome, its effects after intestinal (IT) and multivisceral transplantation (MVT) are not well understood. This study aimed to evaluate the outcomes of GLP-2 therapy post-transplant.
Authors
- M. Cristina Segovia
- Simon Horslen (ORCID: https://orcid.org/0000-0001-5949-7363)
- Joshua Weiner (ORCID: https://orcid.org/0000-0003-3780-1875)
- Thomas Schiano
- Syed‐Mohammed Jafri (ORCID: https://orcid.org/0000-0001-8108-7408)
- Avi Toiv
- Haley D. Justus
- Veronica Lee (ORCID: https://orcid.org/0009-0008-9751-1187)
Institutions
- Columbia University Irving Medical Center (US)
- Henry Ford Hospital (US)
- Mount Sinai Medical Center (US)
- Children's Hospital of Pittsburgh (US)
- Duke University Health System (US)
Publication Details
- Journal
- Intestinal failure.
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1016/j.intf.2025.100134
- Primary Topic
- Clinical Nutrition and Gastroenterology
- Type
- article
- Field-Weighted Citation Impact
- 0.00